Skip to main content
. Author manuscript; available in PMC: 2022 May 16.
Published in final edited form as: Mol Cancer Ther. 2018 Sep 17;17(12):2610–2621. doi: 10.1158/1535-7163.MCT-17-0541

Figure 2. Sorafenib and carfilzomib synergistically inhibit oncogenic growth of HCC cells.

Figure 2.

(A) Hep3B and Bel-7402 cells were treated with sorafenib (2.5 μM) and carfilzomib (0.025 μM) individually or in combination for various times. HCC cell proliferation was determined by the MTS assay.

(B) Carfilzomib enhances the ability of sorafenib to inhibit colony formation of HCC cells. Hep3B and Bel-7402 cells were treated with sorafenib (0.1 μM or 0.5 μM) and carfilzomib (0.01 μM) individually or in combination for about two weeks. The inhibition effects were observed based on the number of colonies formed. The results shown are representative of three independent experiments. All Data were shown as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.